This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Dexanabinol
Description: Dexanabinol is a novel synthetic cannabinoid, lacking psychotropic activity in several animal models. The molecule readily crosses the BBB and is unique among putative neuroprotectors since it combines NMDA blocking activity, free radical scavenging and anti-inflammatory properties in one molecule. In vitro, dexanabinol behaves as a non-competitive NMDA receptor antagonist and blocks NMDA stimulated calcium influx. It also shows potent free radical scavenging properties. In culture it protects from toxicity of free radical generators. In vivo, the compound has anti-inflammatory actions and offers significant neuroprotection in animal models of TBI, stroke and cardiac arrest. It is free of side effects or toxicity when administered by a variety of systemic routes. These observations support its development as a novel, multiple action treatment approach for TBI. Phase I and II studies have shown promising results and support a double blind, randomised, placebo controlled Phase III study as outlined below.
Pink Sheet Pharmos Dexanabinol (Correction)
Pink Sheet Pharmos’ dexanabinol (correction)
Additional information available to subscribers only: